Form 4: Neuraxis CEO Granted 170,659 Restricted Stock Units

Neuraxis, Inc. CEO Brian Allen Carrico received grants of 170,659 Restricted Stock Units under incentive plans, vesting over 36 months.

Summary

• Brian Allen Carrico, CEO and Director of Neuraxis, Inc. (NRXS), was granted a total of 170,659 Restricted Stock Units (RSUs).
• On March 4, 2025, 10,000 RSUs were granted as a bonus under the 2022 Omnibus Securities and Incentive Plan, with a price of $2.18 per share.
• Also on March 4, 2025, an additional 90,640 RSUs were granted under the Long-Term Incentive Plan, also priced at $2.18 per share.
• On January 3, 2025, 70,019 RSUs were granted under the Long-Term Incentive Plan, with a price of $2.42 per share.
• All RSU grants will vest in full at the end of 36 months from their respective grant dates.
• Following these transactions, Mr. Carrico directly beneficially owns 170,659 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: The filing details standard executive compensation in the form of RSU grants, which aligns management's interests with long-term shareholder value. While it indicates ongoing operations and executive retention, it does not present new financial performance data or strategic shifts.

Positives

• The RSU grants align the interests of the CEO, Brian Allen Carrico, with long-term shareholder value through a 36-month vesting schedule.
• The grants demonstrate the company's commitment to executive compensation and retention through its 2022 Omnibus Securities and Incentive Plan and Long-Term Incentive Plan.

Negatives

• The future vesting of 170,659 RSUs will result in dilution for existing shareholders when these shares are issued.

Risks

• Future dilution of existing shareholders upon the vesting and conversion of 170,659 Restricted Stock Units.
• The value of the RSUs is tied to the company's stock performance, meaning a decline in share price would reduce the incentive's effectiveness.

Future Outlook

The granted Restricted Stock Units are scheduled to vest in full at the end of 36 months from their respective grant dates, indicating a long-term incentive structure for the CEO.

Management Comments

• Brian Allen Carrico, Chief Executive Officer and Director, received grants of Restricted Stock Units under the company's incentive plans.

Industry Context

Executive RSU grants are a common form of long-term incentive compensation in the biotechnology and healthcare sectors, aiming to align executive interests with shareholder value creation over several years. This practice is standard across many publicly traded companies to retain key talent and motivate performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) with a multi-year vesting schedule (36 months) is a standard practice for executive compensation in the U.S. public markets, comparable to structures seen at companies like Pfizer, Moderna, or Johnson & Johnson, though the specific quantities and values would vary based on company size and executive role.
• The grants under a "Long-Term Incentive Plan" and "Omnibus Securities and Incentive Plan" are typical frameworks for broad-based equity compensation programs, similar to those adopted by most S&P 500 companies to attract and retain talent.

Corporate Governance

Related Party Transactions

• The grant of 170,659 Restricted Stock Units to Brian Allen Carrico, the Chief Executive Officer and a Director, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential future dilution upon vesting of RSUs; improved alignment of CEO's interests with long-term shareholder value.
• Employees: May signal stability in executive leadership and the company's commitment to incentive-based compensation.
• Management: Provides long-term incentive and compensation tied to company performance.

Next Steps

• The Restricted Stock Units will vest in full at the end of 36 months from their respective grant dates.

Key Dates

Recommendation

This Form 4 filing primarily discloses routine executive compensation in the form of Restricted Stock Units. While it indicates ongoing operations and management alignment, it does not provide new material information regarding the company's financial performance, strategic direction, or operational results that would warrant a change in investment thesis. Therefore, a "hold" recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Neuraxis, NRXS, Brian Allen Carrico, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, SEC Form 4, Long-Term Incentive Plan, Omnibus Securities and Incentive Plan, Stock Grant